RVNC vs. FBLG, ACIU, AMRN, ORGO, ANRO, NBTX, PGEN, TERN, AVIR, and VSTM
Should you be buying Revance Therapeutics stock or one of its competitors? The main competitors of Revance Therapeutics include FibroBiologics (FBLG), AC Immune (ACIU), Amarin (AMRN), Organogenesis (ORGO), Alto Neuroscience (ANRO), Nanobiotix (NBTX), Precigen (PGEN), Terns Pharmaceuticals (TERN), Atea Pharmaceuticals (AVIR), and Verastem (VSTM). These companies are all part of the "pharmaceutical preparations" industry.
FibroBiologics (NASDAQ:FBLG) and Revance Therapeutics (NASDAQ:RVNC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, community ranking, institutional ownership, risk, valuation, analyst recommendations and earnings.
FibroBiologics has higher earnings, but lower revenue than Revance Therapeutics.
In the previous week, Revance Therapeutics had 4 more articles in the media than FibroBiologics. MarketBeat recorded 8 mentions for Revance Therapeutics and 4 mentions for FibroBiologics. Revance Therapeutics' average media sentiment score of 0.34 beat FibroBiologics' score of -0.13 indicating that FibroBiologics is being referred to more favorably in the media.
Revance Therapeutics received 398 more outperform votes than FibroBiologics when rated by MarketBeat users.
97.7% of Revance Therapeutics shares are held by institutional investors. 5.1% of Revance Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
FibroBiologics has a net margin of 0.00% compared to FibroBiologics' net margin of -134.10%.
Revance Therapeutics has a consensus price target of $11.50, suggesting a potential upside of 280.79%. Given FibroBiologics' higher possible upside, analysts plainly believe Revance Therapeutics is more favorable than FibroBiologics.
Summary
Revance Therapeutics beats FibroBiologics on 7 of the 11 factors compared between the two stocks.
Get Revance Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RVNC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Revance Therapeutics Competitors List
Related Companies and Tools
